CICC: Maintains Outperform rating on Genting Hong Kong (01952.HK), raises target price to HK$88

According to the Zhixun Finance APP, China Gold released a research report stating that due to strong demand for NephroCare end terminals from Union Medical Healthcare (01952.HK), sales expectations for NephroCare in 2025 and 2026 have been raised. The profit forecast for 2026 has been adjusted from 12 million yuan to 119 million yuan. Based on the discounted cash flow valuation method, the company maintains an outperform industry rating. As the market begins to factor in the company's expectations for overseas expansion in the pipeline, the bank has raised its target price by 10% to 88.0 Hong Kong dollars, representing a 38.5% upside potential from the current stock price. The company announced its 1H25 performance, with revenue of 446 million yuan, a year-on-year increase of 48%, in line with the bank's expectations.